Immunogenicity and safety of the CoronaVac and BNT162b2 Covid-19 vaccine in patients with inflammatory rheumatic diseases and healthy adults: comparison of different vaccines.

Sevilay BatıbayRezan Koçak UlucaköyZafer GünendiIşıl FidanGülendam BozdayıFeride Nur Göğüş

Published in: Inflammopharmacology (2022)

This study showed that all patients with BNT162b2 vaccine developed immunogenicity in patients with IRD, while there was a decreased antibody response with CoronaVac vaccine compared to that of BNT162b2. In particular, RTX significantly reduces the SC rate.

Keyphrases

coronavirus disease
sars cov
oxidative stress
respiratory syndrome coronavirus